UC Irvine - Chao Family Cancer Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huynh, Bao-An
CLEER, NCT05639933: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Recruiting
2
152
US
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Hoth Therapeutics, Inc., Worldwide Clinical Trials
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
06/25
06/25
KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active, not recruiting
1
276
US
LVGN6051, KEYTRUDA® (pembrolizumab)
Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC
Cancer
12/25
12/25
Smith, Janellen
CLEER, NCT05639933: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Recruiting
2
152
US
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Hoth Therapeutics, Inc., Worldwide Clinical Trials
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
06/25
06/25

Download Options